(Il Sole 24 Ore Radiocor) - Milano, 18 mag - The US medical technology company Boston Scientific announced an investment of 1.5 billion dollars in MiRus, a privately-held company developing and commercializing proprietary biomaterials, implants and procedural solutions for the treatment of cardiovascular and orthpedic diseases, in return for an approximately 34% stake.

As part of the investment, Boston Scientific said it also received an exclusive option to acquire MiRus' trademark Siegel Balloon Expandable Transcatheter Aortic Valve Replacement (TAVR) system, subject to additional payments and the completion of certain milestones. The technology is built on a proprietary rhenium alloy and is the first nickel-free, balloon-expandable TAVR valve intended to restore function and normal blood flow of severely narrowed aortic valves.

MiRus recently initiated the STAR pivotal trial that is evaluating the safety and effectiveness of the three sizes of the Siegel valve in up to 1,025 patients with severe, symptomatic aortic stenosis considered to be at low, intermediate or high risk for surgical complications. Last year, MiRus presented findings from an early feasibility.

study assessing the safety and performance of the device.

(RADIOCOR) 18-05-26 13:44:48 (0304) 5 NNNN